» Articles » PMID: 38867803

Comparison of Atherosclerotic Cardiovascular Disease (ASCVD) and Framingham Risk Scores (FRS) in an Iranian Population

Abstract

Background: Framingham risk score (FRS) and Atherosclerotic Cardiovascular Disease risk score (ASCVDrs) are widely used tools developed based on the American population. This study aimed to compare the ASCVDrs and FRS in an Iranian population.

Method: The participants of the Fasa Adult Cohort Study and the patients of the cardiovascular database of Vali-Asr Hospital of Fasa, aged 40-80 years, were involved in the present cross-sectional study. After excluding non-eligible participants, the individuals with a history of myocardial infarction or admission to the cardiology ward due to heart failure were considered high-risk, and the others were considered low-risk. The discriminative ability of FRS and ASCVDrs was evaluated and compared using receiver operating characteristic curve analysis. The correlation and agreement of ASCVDrs and FRS were tested using Cohen Kappa and Spearman.

Results: Finally, 8983 individuals (mean age:53.9 ± 9.5 y, 49.2 % male), including 1827 high-risk participants, entered the study. ASCVDrs detected a greater portion of participants as high-risk in comparison with FRS (28.7 % vs. 15.7 %). ASVD (AUC:0.794) had a higher discriminative ability than FRS (AUC:0.746), and both showed better discrimination in women. Optimal cut-off points for both ASCVDrs (4.36 %) and FRS (9.05 %) were lower than the original ones and in men. Compared to FRS, ASCVDrs had a higher sensitivity (79.3 % vs. 71.6 %) and lower specificity (64.5 % vs. 65.1 %). FRS and ASCVDrs had a moderate agreement (kappa:0.593,-value<0.001) and were significantly correlated (Spearman:0.772,-value<0.001).

Conclusions: ASCVDrs had a more accurate prediction of cardiovascular events and identified a larger number of people as high-risk in the Iranian population.

Citing Articles

Comparison of 10-year atherosclerotic cardiovascular disease (ASCVD) risk in metropolitan and rural areas of South of Iran.

Zibaeenezhad M, Sayadi M, Pourmontaseri H, Khalili D, Farjam M, Bahramail E Sci Rep. 2025; 15(1):550.

PMID: 39747531 PMC: 11696312. DOI: 10.1038/s41598-024-84366-4.

References
1.
McKeown P, Merlini P, Berzuini C, Bernardinelli L, Peyvandi F, Tubaro M . Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet. 2009; 41(3):334-41. PMC: 2681011. DOI: 10.1038/ng.327. View

2.
Law T, Yan A, Gupta A, Kajil M, Tsigoulis M, Singh N . Primary prevention of cardiovascular disease: global cardiovascular risk assessment and management in clinical practice. Eur Heart J Qual Care Clin Outcomes. 2018; 1(1):31-36. DOI: 10.1093/ehjqcco/qcv002. View

3.
Goff Jr D, Lloyd-Jones D, Bennett G, Coady S, DAgostino R, Gibbons R . 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013; 129(25 Suppl 2):S49-73. DOI: 10.1161/01.cir.0000437741.48606.98. View

4.
Albarqouni L, Doust J, Magliano D, Barr E, Shaw J, Glasziou P . External validation and comparison of four cardiovascular risk prediction models with data from the Australian Diabetes, Obesity and Lifestyle study. Med J Aust. 2019; 210(4):161-167. DOI: 10.5694/mja2.12061. View

5.
Conroy R, Pyorala K, Fitzgerald A, Sans S, Menotti A, De Backer G . Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003; 24(11):987-1003. DOI: 10.1016/s0195-668x(03)00114-3. View